2,919 results match your criteria: "CNRS-Université Lyon I[Affiliation]"
Ann Surg Oncol
January 2025
Hepato-Pancreato-Biliary Surgery and Liver Transplantation, Pôle des Pathologies Digestives et Hépatiques, Hôpital de Hautepierre-Hôpitaux Universitaires de Strasbourg, Université de Strasbourg, Strasbourg, France.
Background: The use of multiagent FOLFIRINOX chemotherapy for pancreatic adenocarcinoma in a neoadjuvant setting has been associated with an increased rate of complete pathological response (CPR) after surgery. This study investigated the long-term outcomes of patients with CPR in a multicenter setting to identify prognostic factors for overall survival (OS) and recurrence-free survival (RFS).
Methods: This retrospective cohort study examined biopsy-proven pancreatic adenocarcinomas with CPR after neoadjuvant chemotherapy or chemoradiotherapy and surgery, between January 2006 and December 2023 across 22 French and 2 Belgian centers.
RMD Open
January 2025
Service de Rhumatologie, Hôpital Cochin, APHP-Centre Université Paris Cité, Paris, France
Objective: To examine the course of interstitial lung disease associated with rheumatoid arthritis (RA-ILD) in France on treatment with Janus kinase inhibitors (JAKis) using the MAJIK-SFR registry.
Methods: Prospective national multicentre observational study identifying patients with RA-ILD from the MAJIK-SFR registry. Pulmonary assessment data were collected at JAKi initiation and follow-up visits (6 months, 12 months and a median of 21 months postinclusion), including chest high-resolution CT (HRCT), pulmonary function tests (forced vital capacity (FVC) and diffusing capacity of the lungs for carbon monoxide (DLCO)), acute exacerbations of ILD, respiratory infections and lung cancers.
ESMO Open
January 2025
Department of Medicine and DRCI, Centre Léon Bérard & Université Claude Bernard Lyon I, Lyon, France.
Background: Paraneoplastic inflammatory syndrome (PIS) with fever and biological inflammation is a rare but severe condition often caused by the systemic production of interleukin 6 (IL-6) by cancer cells. We report on the efficacy of tocilizumab, an anti-IL-6 receptor antibody, in 35 patients with severe PIS.
Patients And Methods: All 35 patients with solid cancers (sarcomas, lung carcinoma, and breast carcinoma) diagnosed with a PIS from 2019 to 2024 treated with tocilizumab were analyzed in this single-center study (health authorities' approval R201-004-478).
Neuro Oncol
December 2024
Genetics Department, Institut Curie, Paris, France.
Background: Medulloblastoma (MB) is one of the most prevalent embryonal malignant brain tumors. Current classification organizes these tumors into four molecular subgroups (WNT, SHH, Group 3, and Group 4 MB). Recently, a comprehensive classification has been established, identifying numerous subtypes, some of which exhibit a poor prognosis.
View Article and Find Full Text PDFClin Neuroradiol
December 2024
Université Lyon I, Université Claude Bernard, Lyon, France.
Purpose: This study aimed to characterize spinal cord microstructure in healthy subjects using high angular resolution diffusion imaging (HARDI) and tractography.
Methods: Forty-nine healthy subjects (18-50 years, divided into 2 age groups) were included in a prospective study. HARDI of the cervical spinal cord were acquired using a 3T MRI scanner with: 64 directions, b‑value: 1000s/mm, reduced field-of-view (zonally magnified oblique multi-slice), and opposed phase-encoding directions.
Ear Hear
December 2024
Institut national de la santé et de la recherche médicale, U1028, Centre National de Recherche Scientifique, UMR5292, Lyon Neuroscience Research Center, Integrative Multisensory Perception and ACTion Team, Lyon, France.
Objectives: Catch-up saccades help to compensate for loss of gaze stabilization during rapid head rotation in case of vestibular deficit. While overt saccades observed after head rotation are obviously visually guided, some of these catch-up saccades occur with shorter latency while the head is still moving, anticipating the needed final eye position. These covert saccades seem to be generated based on the integration of multisensory inputs.
View Article and Find Full Text PDFOncologist
December 2024
Département d'Oncologie Médicale, Institut Paoli-Calmettes, Marseille, France.
Background: In PAOLA-1/ENGOT-ov25, the addition of olaparib to bevacizumab maintenance improved overall survival in patients with newly diagnosed advanced ovarian cancer. We describe the safety profile and quality of life (QoL) of this combination in older patients in PAOLA-1.
Methods: Safety (CTCAE v4.
Ann Oncol
December 2024
Institut Gustave Roussy, Villejuif, France.
Ann Oncol
December 2024
Institut Gustave Roussy, Villejuif.
Br J Dermatol
November 2024
Department of Dermatology, Mayo Clinic, Rochester, Minnesota, USA.
Background: SUNSHINE and SUNRISE demonstrated sustained clinical efficacy of secukinumab in patients with moderate-to-severe hidradenitis suppurativa (HS) through 52 weeks. Patients completing the core trials could enter a 4-year extension trial.
Objectives: To evaluate the long-term efficacy, safety/tolerability, and maintenance of clinical response of secukinumab through Week 104 in the extension trial.
Transpl Int
November 2024
Centre International de Recherche en Infectiologie, INSERM U1111, Université Claude Bernard Lyon I, CNRS UMR5308, Ecole Normale Supérieure de Lyon, University Lyon, Lyon, France.
In transplantation, genetic differences between donor and recipient trigger immune responses that cause graft rejection. Allorecognition, the process by which the immune system discriminates allogeneic grafts, targets major histocompatibility complex (MHC) and minor histocompatibility antigens. Historically, it was believed that allorecognition was solely mediated by the recipient's adaptive immune system recognizing donor-specific alloantigens.
View Article and Find Full Text PDFJ Med Virol
November 2024
CIRI, INSERM U1111, Université Claude Bernard Lyon I, CNRS UMR5308, Ecole Normale Supérieure de Lyon, Lyon, France.
Kidney transplant recipients (KTRs) are highly vulnerable to COVID-19. An intensified scheme of vaccination offers short-term protection to the 50%-75% of KTRs able to develop a germinal center reaction, required for the generation of neutralizing titers of antibodies (NAbs). However, the duration of this vaccinal protection is unknown.
View Article and Find Full Text PDFEur J Cancer
December 2024
Department of Hematology, Hospices Civils de Lyon, CHU Lyon-Sud, Pierre-Bénite, France.
Classic Hodgkin lymphoma (HL) is a distinct entity among hematological malignancies of B-cell origin. It is characterized by its unique histopathological features and generally favorable prognosis. Over the years, advancements in understanding its pathogenesis, coupled with refined diagnostic and evaluation modalities, as well as therapeutic strategies, have significantly transformed the landscape of HL management.
View Article and Find Full Text PDFBull Cancer
October 2024
Service d'oncologie endocrinienne, Département d'imagerie, Gustave-Roussy, F-94805 Villejuif, France.
MANAGING MEDULLARY THYROID CARCINOMA IN 2024: Medullary thyroid carcinoma is a rare neuroendocrine thyroid cancer with a heterogeneous prognosis which has the particularity of being associated with a RET gene mutation, germline in 20-25% of cases in the context of multiple endocrine neoplasia type 2 (NEM2), and somatic in 70% of sporadic cases. It is often diagnosed on a thyroid nodule or in the context of genetic screening. Calcitonin is a biological marker, used for diagnosis, monitoring of therapeutic response and prognostic evaluation.
View Article and Find Full Text PDFLancet Oncol
November 2024
Institut Gustave Roussy, Villejuif, France.
Transpl Int
October 2024
CIRI, INSERM U1111, Université Claude Bernard Lyon I, CNRS UMR5308, Ecole Normale Supérieure de Lyon, University of Lyon, Lyon, France.
Chronic graft rejection represents a significant threat to long-term graft survival. Early diagnosis, understanding of the immunological mechanisms and appropriate therapeutic management are essential to improve graft survival and quality of life for transplant patients. Knowing which immune cells are responsible for chronic vascular rejection would allow us to provide effective and appropriate treatment for these patients.
View Article and Find Full Text PDFCancers (Basel)
October 2024
Department of Neurosurgery, Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, 69677 Bron, France.
: The aim was to determine the complication rate and the predictors of complications and survival in high-grade glioma surgically managed at progression with implantation of Carmustine wafers. : A retrospective series of 53 consecutive patients operated on between 2017 and 2022 was built. : The median age was 55 ± 10.
View Article and Find Full Text PDFBull Cancer
October 2024
Pediatric Hematology Oncology Department, La Timone Children's Hospital, AP-HM, 264, rue St Pierre, 13385 Marseille cedex, France. Electronic address:
J Pers Med
September 2024
Institut of Pharmaceutical and Biological Sciences of Lyon, Claude Bernard Lyon I, 69373 Lyon, France.
In the original publication [...
View Article and Find Full Text PDFN Engl J Med
October 2024
From Université Paris Cité, INSERM Unité 970, Paris Institute for Transplantation and Organ Regeneration (M.S., A.S., M. Raynaud, V.G., G.D., D.Y., J.H., C. Legendre, O.A., C. Lefaucheur, A.L.), the Department of Pathology, Bichat Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP) (A.S.), the Kidney Transplant Department (G.D., C. Lefaucheur) and the Department of Pathology (J. Verine), Saint-Louis Hospital, AP-HP, the Department of Pathology, Necker Hospital, AP-HP (M. Rabant), the Division of Pediatric Nephrology, Necker Hospital, AP-HP, Université Paris Cité (O. Boyer), the Department of Kidney Transplantation, Necker Hospital, AP-HP (M.T., C. Legendre, D.A., O.A., A.L.), and the Division of Pediatric Nephrology, Robert Debré Hospital, AP-HP (J.H.), Paris, the Departments of Pediatric Nephrology (M.F.) and Nephrology (M.L.Q.), Centre Hospitalier Universitaire (CHU) Montpellier, Montpellier, the Pediatric Nephrology Department, Hôpital Universitaire Mère-Enfant, Hospices Civils de Lyon (HCL) (A.-L.S.-L.), and the Department of Transplantation, Edouard Herriot University Hospital, HCL, University of Lyon I (E.M.), Lyon, the Department of Nephrology-Dialysis-Transplantation, CHU de Toulouse, Toulouse (A.B., N.K.), Nantes Université, CHU Nantes, INSERM, Center for Research in Transplantation and Translational Immunology, Unité Mixte de Recherche 1064, Institute of Urology-Nephrology Transplantation of the University Hospital of Nantes, Nantes (R.D., M.G., P.-A.G., S.B.), and the Departments of Pathology (B.C.) and Nephrology, Transplantation, Dialysis, and Apheresis (L.C.), CHU Bordeaux, Bordeaux - all in France; the Division of Nephrology, Department of Medicine, University of Wisconsin School of Medicine and Public Health (B.C.A.), and the Department of Pathology, University of Wisconsin (A.A., W.Z.) - both in Madison; Pediatric Nephrology, David Geffen School of Medicine at UCLA, UCLA Mattel Children's Hospital (P.W.), and Cedars-Sinai Comprehensive Transplant Center (E.H.) - both in Los Angeles; the Department of Pediatrics, University of Washington School of Medicine, Seattle Children's Hospital, Seattle (J.S.); the Division of Pediatric Nephrology, Emory University School of Medicine, Children's Pediatric Institute, Atlanta (R.G.); the Division of Pediatric Nephrology, University of Kansas City, Children's Mercy Hospital, Kansas City, MO (B.A.W.); the Division of Pediatric Nephrology and Hypertension, University of Tennessee Health Science Center, Le Bonheur Children's Hospital, Memphis (R.S.Z.); the Acute Dialysis Units, Pediatric Kidney Transplant, Medical University of South Carolina, Charleston (K.T.); the Division of Pediatric Nephrology, Hypertension, and Apheresis, Washington University School of Medicine and St. Louis Children's Hospital, St. Louis (V.R.D., R.S.D.); the Department of Pediatrics, Robert Wood Johnson Medical School at Rutgers University, New Brunswick, NJ (V.R.D.); the Department of Pediatrics I, University Children Hospital Heidelberg, Heidelberg (B.T.), and the Department of Nephrology and Critical Care Medicine, Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Berlin Institute of Health, Berlin (R.A.C., K.B.) - both in Germany; the Division of Abdominal and Transplantation Surgery, Department of Surgery, Faculty of Medicine, Geneva University Hospitals (T.B.), and the Division of Transplantation Immunology, University Hospital of Geneva (J. Villard), Geneva, and the Division of Clinical Pharmacology, Department of Medicine, and the Department of Laboratory Medicine and Pathology, Lausanne University Hospital, Faculty of Medicine, University of Lausanne, Lausanne (F.R.G.) - all in Switzerland; and the Department of Nephrology and Kidney Transplantation, Vall d'Hebrón University Hospital, Barcelona (O. Bestard).
Background: The heterogeneous clinical presentation of graft microvascular inflammation poses a major challenge to successful kidney transplantation. The effect of microvascular inflammation on allograft outcomes is unclear.
Methods: We conducted a cohort study that included kidney-transplant recipients from more than 30 transplantation centers in Europe and North America who had undergone allograft biopsy between 2004 and 2023.
Ann Oncol
January 2025
Institut Gustave Roussy, Villejuif, France.
Vasc Med
October 2024
Service de Chirurgie Vasculaire et Endovasculaire, Hôpital Louis Pradel, Hospices Civils de Lyon, Bron, France.
Stroke
November 2024
Department of Neuroradiology (A.B.-S., M.H., O.F.E., M.C., E.T., A.M., Y.B.), East Group Hospital, Hospices Civils de Lyon, Bron, France.
Eur J Pediatr
December 2024
Centre de Référence Des Maladies Rénales Rares, Centre de Référence Des Maladies Rares du Calcium Et du Phosphore, Filières Maladies Rares ORKiD, OSCAR Et ERK-Net, Hôpital Femme Mère Enfant, 69677, Bron, France.
Am J Obstet Gynecol
October 2024
Centre international de recherche en infectiologie (CIRI), INSERM U1111, Université Claude Bernard Lyon I, CNRS UMR5308, Ecole Normale Supérieure de Lyon, Lyon, France; Service de Transplantation, Néphrologie et Immunologie Clinique, Hôpital Edouard Herriot, Lyon, France.